Genetic Ace2 Deficiency Accentuates Vascular Inflammation and Atherosclerosis in the ApoE Knockout Mouse
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Rationale: Angiotensin-converting enzyme (ACE)2 opposes the actions of angiotensin (Ang) II by degrading it to Ang 1-7. Objective: Given the important role of Ang II/Ang 1-7 in atherogenesis, we investigated the impact of ACE2 deficiency on the development of atherosclerosis. Methods and Results: C57Bl6 , Ace2 knockout (KO), apolipoprotein E ( ApoE ) KO and ApoE/Ace2 double KO mice were followed until 30 weeks of age. Plaque accumulation was increased in ApoE/Ace2 double KO mice when compared to ApoE KO mice. This was associated with increased expression of adhesion molecules and inflammatory cytokines, including interleukin-6, monocyte chemoattractant protein-1, and vascular cell adhesion molecule-1, and an early increase in white cell adhesion across the whole aortae on dynamic flow assay. In the absence of a proatherosclerotic ( ApoE KO ) genotype, ACE2 deficiency was also associated with increased expression of these markers, suggesting that these differences were not an epiphenomenon. ACE inhibition prevented increases of these markers and atherogenesis in ApoE/ACE2 double KO mice. Bone marrow macrophages isolated from Ace2 KO mice showed increased proinflammatory responsiveness to lipopolysaccharide and Ang II when compared to macrophages isolated from C57Bl6 mice. Endothelial cells isolated from Ace2 KO mice also showed increased basal activation and elevated inflammatory responsiveness to TNF-α. Similarly, selective inhibition of ACE2 with MLN-4760 also resulted in a proinflammatory phenotype with a physiological response similar to that observed with exogenous Ang II (10 −7 mol/L). Conclusions: Genetic Ace2 deficiency is associated with upregulation of putative mediators of atherogenesis and enhances responsiveness to proinflammatory stimuli. In atherosclerosis-prone ApoE KO mice, these changes potentially contribute to increased plaque accumulation. These findings emphasize the potential utility of ACE2 repletion as a strategy to reduce atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,051 · cited 2×
“For example, ACE2 is able to cleave the C-terminal amino acid from vasoactive bradykinin (1-8) (also known as des-Arg9-bradykinin) to form the inactive peptide, bradykinin (1-7) and metabolize des-Arg-kallidin (also known as des-Arg10 Lys-bradykinin).”
BackgroundMethodDonoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
Inflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228
A Human Homolog of Angiotensin-converting Enzyme
Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., & Turner, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002615200 · Cited by 2,009
Role of the T cell in the genesis of angiotensin II–induced hypertension and vascular dysfunction
Guzik, T. J., Hoch, N. E., Brown, K. A., McCann, L. A., Rahman, A., Dikalov, S., Goronzy, J., Weyand, C., & Harrison, D. G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070657 · Cited by 1,736
Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200581200 · Cited by 1,407
Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E–deficient mice
Daugherty, A., Manning, M. W., & Cassis, L. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7818 · Cited by 1,368 · cited 1×
“For example, ACE2 is able to cleave the C-terminal amino acid from vasoactive bradykinin (1-8) (also known as des-Arg9-bradykinin) to form the inactive peptide, bradykinin (1-7) and metabolize des-Arg-kallidin (also known as des-Arg10 Lys-bradykinin).”
BackgroundSolinas, G., Vilcu, C., Neels, J. G., Bandyopadhyay, G. K., Luo, J.-L., Naugler, W., Grivennikov, S., Wynshaw-Boris, A., Scadeng, M., Olefsky, J. M., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.011 · Cited by 513
Ferrario, C. M., & Strawn, W. B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.059 · Cited by 512 · cited 1×
“For example, ACE2 is able to cleave the C-terminal amino acid from vasoactive bradykinin (1-8) (also known as des-Arg9-bradykinin) to form the inactive peptide, bradykinin (1-7) and metabolize des-Arg-kallidin (also known as des-Arg10 Lys-bradykinin).”
BackgroundFerrario, C. M., Trask, A. J., & Jessup, J. A. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00618.2005 · Cited by 385
Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy
Tikellis, C., Johnston, C. I., Forbes, J. M., Burns, W. C., Burrell, L. M., Risvanis, J., & Cooper, M. E. (2003) · Hypertension · doi:10.1161/01.hyp.0000060689.38912.cb · Cited by 350
Self-citationAltered blood pressure responses and normal cardiac phenotype in ACE2-null mice
Gurley, S. B., Allred, A., Le, T. H., Griffiths, R., Mao, L., Philip, N., Haystead, T. A., Donoghue, M., Breitbart, R. E., Acton, S. L., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci16980 · Cited by 334
Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway
Nataraj, C., Oliverio, M. I., Mannon, R. B., Mannon, P. J., Audoly, L. P., Amuchastegui, C. S., Ruiz, P., Smithies, O., & Coffman, T. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7451 · Cited by 308
Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis
Lovren, F., Pan, Y., Quan, A., Teoh, H., Wang, G., Shukla, P. C., Levitt, K. S., Oudit, G. Y., Al-Omran, M., Stewart, D. J., et al. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00331.2008 · Cited by 307
Knowles, J. W., Reddick, R. L., Jennette, J. C., Shesely, E. G., Smithies, O., & Maeda, N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8376 · Cited by 305
Manning, M. W., Cassis, L. A., & Daugherty, A. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000058404.92759.32 · Cited by 303
Improved Islet Morphology after Blockade of the Renin- Angiotensin System in the ZDF Rat
Tikellis, C., Wookey, P. J., Candido, R., Andrikopoulos, S., Thomas, M. C., & Cooper, M. E. (2004) · Diabetes · doi:10.2337/diabetes.53.4.989 · Cited by 286
Self-citationCandido, R., Jandeleit-Dahm, K. A., Cao, Z., Nesteroff, S. P., Burns, W. C., Twigg, S. M., Dilley, R. J., Cooper, M. E., & Allen, T. J. (2002) · Circulation · doi:10.1161/01.cir.0000021122.63813.32 · Cited by 261
Self-citationOUDIT, G., KASSIRI, Z., PATEL, M., CHAPPELL, M., BUTANY, J., BACKX, P., TSUSHIMA, R., SCHOLEY, J., KHOKHA, R., & PENNINGER, J. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.04.007 · Cited by 245
A Simple Method of Isolating Mouse Aortic Endothelial Cells
Kobayashi, M., Inoue, K., Warabi, E., Minami, T., & Kodama, T. (2005) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12.138 · Cited by 238
Jurewicz, M., McDermott, D. H., Sechler, J. M., Tinckam, K., Takakura, A., Carpenter, C. B., Milford, E., & Abdi, R. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070707 · Cited by 210
Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis
Candido, R., Allen, T. J., Lassila, M., Cao, Z., Thallas, V., Cooper, M. E., & Jandeleit-Dahm, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000124061.78478.94 · Cited by 195
Self-citationACE2 Deficiency Modifies Renoprotection Afforded by ACE Inhibition in Experimental Diabetes
Tikellis, C., Bialkowski, K., Pete, J., Sheehy, K., Su, Q., Johnston, C., Cooper, M. E., & Thomas, M. C. (2008) · Diabetes · doi:10.2337/db07-1212 · Cited by 182
Self-citationVasoprotective and Atheroprotective Effects of Angiotensin (1-7) in Apolipoprotein E–Deficient Mice
Tesanovic, S., Vinh, A., Gaspari, T. A., Casley, D., & Widdop, R. E. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.204453 · Cited by 151
A Role of Matrix Metalloproteinase-8 in Atherosclerosis
Laxton, R. C., Hu, Y., Duchene, J., Zhang, F., Zhang, Z., Leung, K.-Y., Xiao, Q., Scotland, R. S., Hodgkinson, C. P., Smith, K., et al. (2009) · Circulation Research · doi:10.1161/circresaha.109.200279 · Cited by 136
Interactions between Renin Angiotensin System and Advanced Glycation in the Kidney
Thomas, M. C., Tikellis, C., Burns, W. M., Bialkowski, K., Cao, Z., Coughlan, M. T., Jandeleit-Dahm, K., Cooper, M. E., & Forbes, J. M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010013 · Cited by 136
Self-citationTissue renin angiotensin systems
Ré, R. N. (2004) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00124-x · Cited by 132
Tissue renin-angiotensin systems. Their role in cardiovascular disease.
Lee, M. A., Böhm, M., Paul, M., & Ganten, D. (1993) · PubMed · Cited by 121
Renin-Angiotensin System and Atherothrombotic Disease: From Genes to Treatment
Jacoby, D. S., & Rader, D. J. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.10.1155 · Cited by 118 · cited 1×
“For example, ACE2 is able to cleave the C-terminal amino acid from vasoactive bradykinin (1-8) (also known as des-Arg9-bradykinin) to form the inactive peptide, bradykinin (1-7) and metabolize des-Arg-kallidin (also known as des-Arg10 Lys-bradykinin).”
BackgroundProgression of Cardiovascular Damage: The Role of Renin–Angiotensin System Blockade
Probstfield, J. L., & O’Brien, K. D. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.006 · Cited by 100
Platelet Activation in Essential Hypertension: Implications for Antiplatelet Treatment
Gkaliagkousi, Ε., Passacquale, G., Δούμα, Σ., Zamboulis, C., & Ferro, A. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2009.247 · Cited by 88
Woollard, K. J., Suhartoyo, A., Harris, E. E., Eisenhardt, S. U., Jackson, S. P., Peter, K., Dart, A. M., Hickey, M. J., & Chin-Dusting, J. P. F. (2008) · Circulation Research · doi:10.1161/circresaha.108.180273 · Cited by 68
Self-citationKeidar, S., Attias, J., Coleman, R., WIRTH, K. J., Schölkens, B. A., & Hayek, T. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200001000-00008 · Cited by 65
Nakamura, K., Koibuchi, N., Nishimatsu, H., Higashikuni, Y., Hirata, Y., Kugiyama, K., Nagai, R., & Sata, M. (2008) · Hypertension Research · doi:10.1291/hypres.31.1953 · Cited by 38
Reduced Cardiovascular Reactivity to Stress but Not Feeding in Renin Enhancer Knockout Mice
JACKSON, K., HEAD, G., MORRIS, B., CHINDUSTING, J., JONES, E., LAGRECA, L., & MAYOROV, D. (2007) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2007.02.010 · Cited by 34
Self-citationChen, D., Greca, L. L., Head, G., Walther, T., & Mayorov, D. (2009) · Hypertension Research · doi:10.1038/hr.2009.59 · Cited by 30
Self-citationEkholm, M., Kahan, T., Jörneskog, G., Bröijersén, A., & Wallén, N. H. (2009) · Thrombosis Research · doi:10.1016/j.thromres.2008.12.040 · Cited by 27 · cited 1×
“For example, ACE2 is able to cleave the C-terminal amino acid from vasoactive bradykinin (1-8) (also known as des-Arg9-bradykinin) to form the inactive peptide, bradykinin (1-7) and metabolize des-Arg-kallidin (also known as des-Arg10 Lys-bradykinin).”
Background
Cited by
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.-C., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317015 · Cited by 1,882
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B., & Wu, J. C. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0413-9 · Cited by 1,409
The ACE2/angiotensin-(1-7)/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)
Santos, R. A. S., Sampaio, W. O., Alzamora, A. C., Motta-Santos, D., Alenina, N., Bader, M., & Campagnole-Santos, M. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2016 · Cited by 1,144
The Science Underlying COVID-19: Implications for the Cardiovascular System
Liu, P. P., Blet, A., Smyth, D., & Li, H. (2020) · Circulation · doi:10.1161/circulationaha.120.047549 · Cited by 800
Tikellis, C., & Thomas, M. C. (2012) · International Journal of Peptides · doi:10.1155/2012/256294 · Cited by 624
Self-citation
Metadata
- Authors
- Thomas, M. C., Pickering, R. J., Tsorotes, D., Koitka, A., Sheehy, K., Bernardi, S., Toffoli, B., Nguyen-Huu, T.-P., Head, G. A., Fu, Y., Chin-Dusting, J., Cooper, M. E., & Tikellis, C.
- Venue
- Circulation Research
- Published
- 2010-10
- Volume
- 107
- Issue
- 7
- Pages
- 888-897
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2163610648
- Cited by
- 232
- References
- 41
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.